"Alkynes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Hydrocarbons with at least one triple bond in the linear portion, of the general formula Cn-H2n-2.
| Descriptor ID |
D000480
|
| MeSH Number(s) |
D02.455.326.397
|
| Concept/Terms |
Alkynes- Alkynes
- Acetylenic Compounds
- Acetylenes
|
Below are MeSH descriptors whose meaning is more general than "Alkynes".
Below are MeSH descriptors whose meaning is more specific than "Alkynes".
This graph shows the total number of publications written about "Alkynes" by people in this website by year, and whether "Alkynes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 2 | 2 |
| 2011 | 0 | 6 | 6 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 5 | 5 |
| 2014 | 0 | 4 | 4 |
| 2015 | 0 | 9 | 9 |
| 2016 | 0 | 2 | 2 |
| 2017 | 0 | 3 | 3 |
| 2018 | 0 | 4 | 4 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 3 | 4 |
| 2021 | 1 | 6 | 7 |
| 2022 | 0 | 2 | 2 |
| 2024 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Alkynes" by people in Profiles.
-
Low CD4 counts predict excessive weight gains during first-line treatment for HIV. J Antimicrob Chemother. 2024 Sep 03; 79(9):2369-2378.
-
Characterizing HIV drug resistance in cases of vertical transmission in the VESTED randomized antiretroviral treatment trial. J Acquir Immune Defic Syndr. 2024 Aug; 96(4):385-392.
-
Assessment of weight gain in adult patients living with HIV receiving first-line dolutegravir-based or efavirenz-based ART regimens in routine care clinics in Tshwane district, South Africa: An observational study. HIV Med. 2024 Jul; 25(7):826-839.
-
Population Pharmacokinetic Modeling and Simulation of Rifapentine Supports Concomitant Antiretroviral Therapy with Efavirenz and Non-Weight Based Dosing. Antimicrob Agents Chemother. 2022 09 20; 66(9):e0238521.
-
Concentration-response relationships of dolutegravir and efavirenz with weight change after starting antiretroviral therapy. Br J Clin Pharmacol. 2022 03; 88(3):883-893.
-
Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children. N Engl J Med. 2021 12 30; 385(27):2531-2543.
-
The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir disoproxil fumarate/emtricitabine/efavirenz. AIDS. 2021 12 15; 35(Suppl 2):S117-S125.
-
CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz. Clin Infect Dis. 2021 12 06; 73(11):e3902-e3909.
-
A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug-Drug Interactions With Antiretroviral and Antituberculosis Treatment. Clin Pharmacol Ther. 2021 10; 110(4):1057-1065.
-
Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine. AIDS. 2021 04 01; 35(5):759-767.